Stockreport

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Clearmind Medicine Inc.  (CMND) 
PDF Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 [Read more]